Related Experiment Video
Updated: Mar 13, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Effects of VPA on the Expression of Notch Signaling Pathway in Multiple Myeloma RPMI 8226 Cell Line]
Lian Qiao1, Yue Yang2, Rui-Juan Zhao2
1Hebei University of Traditional Chinese Medicine, Shijiazhuang 050200, Hebei Province, China.
Objective:
To investigate the effects of valproic acid(VPA) on the expression of intracellular domain of Notch1 (ICN1) and Hes1 in multiple myeloma RPMI 8226 cell line.
Methods:
Experiments were divided into 4 group: blank control group and groups of cells treated with VPA of different concentration (2, 4, 8 mmol/L), the cell proliferation was detected by MTT method, RT-PCR was applied to detect the mRNA expression level of ICN1 and Hes1. Western blot was used to detect the protein expression of ICN1 and Hes1.
Results:
The proliferation of the RPMI 8226 cell was obviously inhibited by different concentration of VPA (2, 4, 8 mmol/L) at the same time. The same concentration of VPA was used to treat RPMI8226 cell for different time (24, 48, 72 h), the cell proliferation was obviously inhibited. Compared with control group, the mRNA and protein expression of ICN1 was significantly depressed at different concentration of VPA(2, 4, 8 mmol/L) for 48 h (P<0.05). Compared with control group, the mRNA and protein expression of Hes1 was depressed at different concentration 2, 4, 8 mmol/L)of VPA for 48 h (P<0.05).
Conclusion:
VPA inhibits the proliferation of the RPMI 8226 cell in a time- and dose- dependent manner; VPA down-regulates the mRNA and protein expression level of ICN1 and Hes1 in RPMI8226 cell; thus VPA might inhibit cell proliferation possibly through the inhibition of Notch signaling pathway in multiple myeloma cells.
Insights
Valproic acid (VPA) inhibits multiple myeloma cell proliferation in a dose- and time-dependent manner. VPA down-regulates Notch signaling pathway components, suggesting a potential therapeutic mechanism.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multiple myeloma is a hematological malignancy characterized by uncontrolled plasma cell proliferation.
- The Notch signaling pathway plays a role in cell proliferation and differentiation, and its dysregulation is implicated in various cancers.
Purpose of the Study:
- To investigate the effects of valproic acid (VPA) on the expression of the intracellular domain of Notch1 (ICN1) and Hes1 in the RPMI 8226 multiple myeloma cell line.
- To determine if VPA affects multiple myeloma cell proliferation.
Main Methods:
- RPMI 8226 cells were treated with varying concentrations of VPA (2, 4, 8 mmol/L) or for different durations (24, 48, 72 hours).
- Cell proliferation was assessed using the MTT assay.
- mRNA and protein expression levels of ICN1 and Hes1 were quantified using RT-PCR and Western blot, respectively.
Main Results:
- VPA significantly inhibited RPMI 8226 cell proliferation in a dose- and time-dependent manner.
- VPA treatment led to a significant decrease in both mRNA and protein expression of ICN1 and Hes1 compared to control groups.
- The observed effects were statistically significant (P<0.05).
Conclusions:
- Valproic acid demonstrates anti-proliferative effects on multiple myeloma cells.
- VPA down-regulates key components of the Notch signaling pathway, including ICN1 and Hes1.
- Inhibition of the Notch signaling pathway may represent a mechanism by which VPA exerts its anti-cancer effects in multiple myeloma.
